BioSpace News Archive

Quest Diagnostics, the world’s leading provider of diagnostic information services, announced that its Board of Directors declared a quarterly cash dividend of $0.56 per share, payable on October 21, 2020 to shareholders of record of Quest Diagnostics common stock on October 6, 2020.

StageZero Life Sciences, Ltd (TSX:SZLS) (“StageZero” or the “Company”) is pleased to report that shareholders voted in favour of all items of business, including the election of all nominee directors listed in the Company’s management information circular dated June 29, 2020 (the “Circular”), at its annual and special meeting of shareholders held on August 17, 2020 (the “Meeting”).

Inhibrx, Inc. (“Inhibrx”) (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a price to the public of $17.00 per share.

As the search for COVID-19 therapies continues, convalescent plasma—distilled from the blood of people who have recovered from COVID-19—has emerged as a promising treatment option.

Putting Rare Diseases Patients First!® is pleased to announce the submission of a Citizen’s Petition to add Sickle Cell Disease to FDA’s Tropical Disease Priority Review Voucher List.

Isotopia Molecular Imaging is pleased to announce that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for no-carrier-added Lutetium-177 (n.c.a. Lu177), a medical radioisotope.

A new clinical trial found consuming cranberry juice containing 44 mg of proanthocyanidins (or “PACs”) per 240-mL serving twice daily for eight weeks resulted in a 20% reduction in the H. pylori infection rate in Chinese adult participants, when compared to those consuming lower amounts of juice and a placebo

International Isotopes Inc. (OTCQB: INIS) (the “Company” or “INIS”) announces its financial results for the three and six months ended June 30, 2020.

World over, vision care has made some significant advances on the adoption of new population health approaches, especially in developed countries, underpinning the evolution of the vision care market.

Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera’s first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes